 FDA has been unable to travel to China to conduct the required site inspection resulting in delayed action on the BLA Coherus and Junshi Biosciences are actively engaged in ongoing discussions with the FDA to support the inspections and gain approval of toripalimab for patients with NPC in the U.S. as quickly ... The post Coherus and Junshi Biosciences Share Update on the FDA Review of the Biologics License Application BLA for Toripalimab as Treatment for Recurrent or Metastatic Nasophar... 